Ian Krop, MD
Enriched profileSection Chief, Medical Oncology and Hematology and Deputy Director for Clinical Affairs, Yale Cancer Center and Smilow Cancer Hospital; Professor of Internal Medicine (Medical Oncology), Yale School of Medicine · Yale Cancer Center
Ian Krop is Section Chief, Medical Oncology and Hematology and Deputy Director for Clinical Affairs, Yale Cancer Center and Smilow Cancer Hospital; Professor of Internal Medicine (Medical Oncology), Yale School of Medicine at Yale Cancer Center. OpenAlex indexes 881 publications with 43,223 citations (h-index 101); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Ian Krop, MD PHD, is Section Chief, Medical Oncology and Hematology and Deputy Director for Clinical Affairs, Yale Cancer Center and Smilow Cancer Hospital. The public record shows 881 publications with 43,223 citations (h-index 101), centered on HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 21 companies, 1 NIH-funded awards (2024–2025).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: HER2/EGFR in Cancer Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 268.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Sponsor: National Cancer Institute (NCI)
- Trastuzumab and Vinorelbine in Advanced Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20255 payments$20,200openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Letrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2024–2025 per NIH RePORTER. The latest:
- Project 2: Combination immunotherapy approaches to overcome therapeutic resistance in HER2-positive breast cancer
Dana-Farber Cancer Inst
FY2023$292,601P50CA168504
Congress activity
Updated 27 Aug 2026
209 congress contributions (2007–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 1220: Spatial transcriptomics revealed potential resistance and response factors of sacituzumab govitecan in metastatic breast cancer.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Clinical cancer research
Clinical Trial2026 - Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Journal of the National Cancer Institute
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerArticle3,813 citations2012
- 023rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Article2,067 citations2016
- 03Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerArticle1,997 citations2019
- 04CDK4/6 inhibition triggers anti-tumour immunityArticle1,547 citations2017
- 05Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerArticle1,329 citations2019
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ian-krop-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/ian-krop-69836a75
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
bcrf.org/blog/bcrf-2023-podcast-ian-krop-breast-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Other
yalemedicine.org/podcasts/2025-yca-0608-podcast-krop
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗ - X / Twitter
x.com/DFCI_BreastOnc/status/1928941291259281769
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - PhD (Cellular and Molecular Biology)
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- Chief Clinical Research Officer
Yale Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Director
Yale Cancer Center Clinical Trials Office
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswise.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ynhh.org ↗
Media & interviews
press, podcasts and appearances- Guest
"Yale Cancer Answers" (WNPR/Connecticut Public Radio) episode "Increasing Access to Clinical Trials," aired January 12
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Maryam Lustberg, MD
Yale Cancer Center
Pamela Kunz, MD
Yale Cancer Center
Anne Chiang, MD
Yale Cancer Center
Charles Matouk, MD
Yale Cancer Center